24 November 2021 - Early treatment study
Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial
et al., medRxiv, doi:10.1101/2021.11.22.21266690 (Preprint)
Small RCT 116 mITT patients in the USA, 59 treated with favipiravir, showing no significant differences with treatment.
|
risk of hospitalization, 89.0% lower, RR 0.11, p = 0.06, treatment 0 of 75 (0.0%), control 4 of 74 (5.4%), NNT 18, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm). With the observed event rates, ~11 more patients per arm would result in statistical significance.
|
|
risk of ER visit, 29.5% lower, RR 0.70, p = 0.56, treatment 5 of 75 (6.7%), control 7 of 74 (9.5%), NNT 36.
|
|
risk of no recovery, 16.0% lower, RR 0.84, p = 0.43, treatment 65, control 70, initial resolution of symptoms.
|
|
viral shedding, 31.6% higher, RR 1.32, p = 0.24, treatment 59, control 57.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Holubar et al., 11/24/2021, Double Blind Randomized Controlled Trial, USA, North America, preprint, 26 authors, average treatment delay 5.0 days.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.